Oncology · Medical Literature
CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma.
Abstract
IntroductionThere is currently no biomarker for progression-free survival (PFS) for patients undergoing treatment for metastatic renal cell carcinoma (RCC). The aim of our study was to evaluate computed tomography perfusion (CTp) blood flow as an early marker of PFS in patients with mRCC treated with targeted agents.MethodsAssociations between CTp blood flow and PFS were evaluated from prospective randomized evidence using univariable and multivariable Cox proportional hazards regression models with Harrell's concordance index (c-index) in patients with mRCC randomized to receive one of three targeted agents (everolimus, bevacizumab, or pazopanib). Analyses included baseline tumor CTp blood flow (BF0) and changes in blood flow after 8 weeks of therapy (ΔBF). Demographic and clinical prognostic factors (International mRCC Database Consortium [IMDC] risk score and ECOG performance) were included in the models as covariates.ResultsThe median PFS of the 55-patient cohort was 0.80 years (95% CI: 0.76-1.38 years), with no significant difference among the targeted agents. ΔBF and BF0 were significantly associated with PFS on univariable analysis (p=0.002 and p=0.013, respectively). Multivariable analyses incorporating all the above factors indicated that higher baseline BF0 (>166 mL/min/100g) and reduced ΔBF (<2.8%) were significantly associated with longer PFS (p<0.02).ConclusionCTp blood flow may have utility as independent prognostic and early surrogate markers of PFS in mRCC patients treated with targeted agents, surpassing clinical markers like IMDC risk classification. Higher baseline perfusion (BF0) delineates tumors responsive to targeted therapy, while reductions in perfusion (ΔBF) just 8 weeks after starting treatment are associated with longer PFS. These findings arise from randomized evidence, warranting further evaluations.
Clinical relevance
Can CT perfusion (CTp) tumor blood flow — measured at baseline and after 8 weeks of targeted therapy — serve as an early imaging biomarker of progression-free survival in patients with metastatic renal cell carcinoma? __SNAPSHOT__ {"studyDesign":"Prospective, randomized, comparative cohort study with biomarker sub-study embedded within a randomized clinical trial; Cox proportional hazards regression (univariable and multivariable) with Harrell's concordance index (c-index) used for prognostic modeling","setting":"Not reported (prospective randomized trial setting implied; specific institution(s) or country not stated in the abstract)","sampleSize":"n = 55 patients (treatment arm breakdown not reported in the abstract)","population":"Adults with metastatic renal cell carcinoma (mRCC) enrolled in a randomized trial and randomized to one of three targeted agents; detailed histologic subtype distribution, IMDC risk category breakdown, ECOG performance status distribution, and prior therapy history not reported in the abstract","intervention":"CT perfusion (CTp) imaging at baseline (BF0) and at 8 weeks of targeted therapy (ΔBF = change in blood flow), evaluated as prognostic biomarkers of PFS; treatment agents included everolimus, bevacizumab, or pazopanib","comparator":"No separate imaging comparator group; the study compared the three active targeted therapy arms against each other for PFS, and assessed CTp parameters across the full cohort as covariates in prognostic models","primaryOutcome":"Association between CTp blood flow parameters (BF0 and ΔBF) and progression-free survival (PFS), quantified via Cox proportional hazards regression and Harrell's c-index","followUp":"Not explicitly reported in the abstract; PFS events used to anchor regression models; median PFS was 0.80 years (95% CI: 0.76–1.38 years)","fundingSource":"Not reported"}
Key findings
The 55-patient cohort had a median PFS of 0.80 years (95% CI: 0.76–1.38 years). No statistically significant difference in PFS was observed among the three targeted agents (everolimus, bevacizumab, pazopanib; p-value for inter-arm comparison not reported). On univariable analysis, both ΔBF (8-week change in blood flow) and BF0 (baseline blood flow) were significantly associated with PFS (p = 0.002 and p = 0.013, respectively). Multivariable analysis results — including hazard ratios, confidence intervals, and the magnitude of c-index improvement — are not fully reported in the available abstract. Absolute effect sizes (e.g., hazard ratios with confidence intervals for BF0 and ΔBF), NNT/NNH, and specific c-index values were not reported in the abstract excerpt provided. Covariates included in multivariable models were IMDC risk score and ECOG performance status. Adverse events related to CTp imaging (e.g., radiation dose, contrast-related complications) were not reported in the abstract.
Practice implications
This study provides prospective randomized-trial evidence that CT perfusion blood flow — both at baseline and its early change at 8 weeks — is statistically significantly associated with PFS in mRCC patients receiving targeted therapy. This is a meaningful signal: unlike anatomic size-based response criteria (RECIST), CTp captures functional vascular changes, which may precede morphological tumor shrinkage and could theoretically allow earlier identification of non-responders. However, several important limitations in interpreting these findings must be acknowledged. First, only the abstract was available for review; full multivariable model outputs, hazard ratios, confidence intervals, and c-index values were not reported in the provided text, preventing complete assessment of the magnitude and clinical importance of the observed associations. Second, the cohort is small (n = 55), which limits statistical power, precision of effect estimates, and the robustness of multivariable modeling. Third, these agents (everolimus, bevacizumab, pazopanib) represent an earlier generation of mRCC systemic therapy; the findings may not be directly generalizable to contemporary regimens involving immune checkpoint inhibitors (e.g., nivolumab/ipilimumab, pembrolizumab/axitinib). Fourth, no clinical utility threshold for CTp blood flow (i.e., a validated cut-off to guide treatment decisions) is established by this study. The finding of statistical significance on both univariable and multivariable analyses is promising but requires validation in larger, independent, prospectively designed biomarker studies before CTp can be considered a clinically actionable decision tool. Practice should not change on the basis of this study alone. __LIMITATIONS__ Small sample size (n = 55) limits statistical power, precision of effect estimates, and the robustness of multivariable adjustment for confounders,Only an abstract was available for review; full multivariable results, hazard ratios, confidence intervals, c-index values, and model diagnostics were not reported in the provided text,No validated clinical decision threshold (cut-off value) for CTp blood flow is established; therefore, how to operationalize these findings at the bedside is undefined,Targeted agents studied (everolimus, bevacizumab, pazopanib) are not representative of current first-line immunotherapy-based combinations, limiting contemporary generalizability,CT perfusion carries incremental radiation exposure and requires technical standardization across institutions, limiting real-world scalability,The study design evaluated CTp as a prognostic/predictive biomarker but does not establish whether CTp-guided treatment modification improves outcomes (i.e., no interventional arm based on CTp results),Histologic subtype distribution, prior therapy details, and IMDC risk category breakdown are not reported in the abstract, limiting assessment of population generalizability,Funding source not reported, precluding assessment of potential sponsorship bias,Statistical significance on univariable analysis does not confirm clinical actionability; clinical importance of the magnitude of association remains unquantifiable from the available abstract __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In a prospective randomized cohort of 55 mRCC patients, CT perfusion blood flow — both at baseline and the 8-week on-treatment change — was statistically significantly associated with progression-free survival across three targeted therapy regimens, providing early-phase evidence for CTp as a functional imaging biomarker. However, the small sample size, incomplete reporting of effect sizes in the available abstract, and use of therapies predating current immunotherapy-based standards substantially limit the immediate clinical applicability of these findings. This study is hypothesis-generating and warrants prospective validation in larger, contemporary cohorts before CTp blood flow can be incorporated into mRCC treatment monitoring algorithms.